Active Contrast Encoding MRI for Breast Cancer

乳腺癌主动对比编码 MRI

• 批准号: 9765502
• 负责人: Sungheon Gene Kim
• 金额: $ 55.02万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-03-01 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9765502
• 关键词: 3-Dimensional; Address; Angiogenesis Inhibitors; Animals; Area; Blood Cells; Blood Vessels; Blood flow; Blood specimen; Breast Cancer Model; Breast Magnetic Resonance Imaging; Cancer Etiology; Cancer Model; Cell Death; Cell Size; Cells; Cellular Membrane; Cessation of life; Clinical; Combined Modality Therapy; Contrast Media; Cytotoxic agent; Data; Development; Diffusion Magnetic Resonance Imaging; Distant; Distant Metastasis; Drug Delivery Systems; Excision; Extracellular Space; Failure; Funding; Gadolinium; Harvest; Human; Image; Imaging technology; Immune; Immunotherapy; Ion Channel; Life; Magnetic Resonance Imaging; Malignant Neoplasms; Measurement; Measures; Methods; Monitor; Mus; Neoadjuvant Therapy; Neoplasm Metastasis; Operative Surgical Procedures; Pathologic; Pathology; Patients; Perfusion; Physiologic pulse; Plasma; Positron-Emission Tomography; Property; Protocols documentation; Protons; Radial; Research; Scanning; Surface; Techniques; Testing; Three-Dimensional Imaging; Time; Tissues; Translating; Triplet Multiple Birth; Uncertainty; Validation; Vascular Permeabilities; Water; Woman; base; bioluminescence imaging; cancer cell; cancer diagnosis; cancer imaging; cancer therapy; chemotherapy; clinical application; cohort; contrast enhanced; cytotoxic; data acquisition; drug discovery; experimental study; grasp; image reconstruction; imaging modality; improved; in vivo; in vivo imaging; innovation; interstitial; malignant breast neoplasm; metabolic rate; novel; novel strategies; response; temporal measurement; treatment response; tumor; water channel

PROJECT SUMMARY Despite recent development of various new approaches to therapy, breast cancer remains the second leading cause of cancer death in women. Treatment with anti-angiogenic drugs combined with conventional cytotoxic drugs or immunotherapy is a promising means of treating aggressive cancer. Anti-angiogenic drugs are thought to temporarily normalize abnormal vasculature and paradoxically increase blood flow and hence delivery of drug and effector immune cells to tumors. However, a substantial proportion of patients do not respond to this combination therapy and it is unclear whether the failure is due to failure of the anti-angiogenic to normalize the vasculature or failure of the cytotoxic drugs or immune cells to kill cancer cells. It is therefore necessary to assess both blood flow and cell death to elucidate the mechanism and to optimize the combination treatments. In this proposal we investigate a single MRI acquisition and analysis that will allow assessment of both. Dynamic contrast enhanced (DCE) MRI has been widely used as an important part of most clinical MRI exams for diagnosis of cancer, and it holds high potential as a single MRI method to estimate both perfusion parameters (such as, flow, F, vascular volume fraction, vp, and vascular permeability-surface area product, PS) and cellular parameters (such as, interstitial volume fraction, ve, and intracellular water life time, τi). Recently, we developed a novel data acquisition method, namely active contrast encoding (ACE)-MRI, which measures dynamic data together with pre-contrast T1 and B1 that are critical for measurement of perfusion and cellular parameters. ACE-MRI is also implemented with a fast 3D imaging method to acquire high-spatial and high- temporal resolution data using a 3D golden-angle ultra-short echo-time (UTE) sequence and an image reconstruction method to combine both compressed sensing and parallel imaging, also known as GRASP (Golden-angle RAdial Sparsity and Parallel). In this study, we plan to further develop ACE-MRI for accurate estimation of contrast agent concentration in vascular plasma and tissue using a direct blood sampling method (Aim 1), and to assess the association of τi with tumor metabolic rate and treatment response in comparison with 18F-FDG-PET and pathology (Aim 2). Overall, the ACE-MRI parameters will be used to assess treatment response and metastatic potential (Aim 3). This study will be conducted with murine and human breast cancer models at a 7T small animal MRI scanner. However, the methods developed in this study can be easily translated to clinical applications as it is used on a UTE sequence readily available on most clinical scanners.

项目概要 尽管最近开发了各种新的治疗方法，但乳腺癌仍然是第二大癌症 女性癌症死亡的原因。抗血管生成药物联合常规细胞毒药物治疗 药物或免疫疗法是治疗侵袭性癌症的一种有前途的方法。抗血管生成药物有 人们认为可以暂时使异常的脉管系统正常化，并相反地增加血流量，因此 将药物和效应免疫细胞递送至肿瘤。然而，相当一部分患者并不 对这种联合疗法有反应，但尚不清楚失败是否是由于抗血管生成药物的失败所致 使脉管系统正常化或细胞毒性药物或免疫细胞无法杀死癌细胞。因此是 有必要评估血流和细胞死亡，以阐明机制并优化 联合治疗。在本提案中，我们研究了单个 MRI 采集和分析，这将允许 对两者的评估。 动态对比增强（DCE）MRI作为大多数临床MRI的重要组成部分已被广泛应用 癌症诊断检查，作为单一 MRI 方法来估计灌注具有很高的潜力 参数（例如流量 F、血管体积分数 vp 和血管通透性表面积乘积 PS） 和细胞参数（例如，间隙体积分数 ve 和细胞内水寿命 τi）。最近， 我们开发了一种新颖的数据采集方法，即主动对比编码（ACE）-MRI，它测量 动态数据以及对比前 T1 和 B1，对于灌注和细胞测量至关重要 参数。 ACE-MRI 还采用快速 3D 成像方法来实现，以获得高空间和高 使用 3D 黄金角超短回波时间 (UTE) 序列和图像的时间分辨率数据 结合压缩感知和并行成像的重建方法，也称为GRASP （黄金角径向稀疏性和并行）。 在本研究中，我们计划进一步开发 ACE-MRI，以准确估计造影剂浓度 使用直接血液采样方法（目标 1）对血管血浆和组织进行分析，并评估 τi 的关联 与 18F-FDG-PET 和病理学相比，肿瘤代谢率和治疗反应（目标 2）。 总体而言，ACE-MRI 参数将用于评估治疗反应和转移潜力（目标 3）。 这项研究将在 7T 小动物 MRI 扫描仪上使用小鼠和人类乳腺癌模型进行。 然而，本研究中开发的方法可以很容易地转化为临床应用，因为它用于 UTE 序列可在大多数临床扫描仪上轻松使用。